Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

Trial ID: NCT06356662

Interventional - Phase 1 - Recruiting

To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.

Conditions

• Parkinson Disease

Interventions

• Tenofovir Disoproxil Fumarate

Eligibility

Inclusion criteria

• 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24

Exclusion criteria

• 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders
• 2: Or have received deep brain stimulation and other brain surgery
• 3: Abnormal liver and kidney function
• 4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)
• 5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence
• 6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor
• 7: Pregnant or lactating women and seniors over 65 years of age
• 8: Allergy or other contraindications to the investigational drug

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows